Q3FY26 Strong numbers; CDMO takes breather but Generics solid Sales stood at 1778 crore, reflecting a ~26% YoY growth driven by Generics. While Generic FDF grew 39% to 607 crore, Generic APIs ~36% to 720 crore. The CDMO business on the other hand grew just 2% to 408 crore. EBITDA grew 68% YoY to 480 crore with a margin of 27%, a significant 685 bps improvement driven by 406 bps GPM improvement. PAT stood 253.1 crore a 180% YoY growth. Long term prospects remain robust- Despite apparent slowdown in the CDMO business, the margin performance was strong on account of strong...